Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of increasing the availability of medicinal cannabis for epilepsy patients in Devon.

The licenced cannabis-based medicine Epidyolex is available on the National Health Service in England for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This follows approval from the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence (NICE).

NICE has assessed the available evidence, and concluded that there is a clear need for more evidence to support routine prescribing and funding decisions of unlicensed cannabis-based products for medicinal use. NHS funding decisions follow established procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.